Boehringer receives SBTi validation for CO2 reduction targets
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
Search
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.
Victor Emenike
Victor Emenike embraces exploration
Karla Alvarez
Karla Alverez: ways to learn and grow
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Rabies? Not in Mexico!
Mexico has been a rabies-free country for the last five years. How does Mexico achieve this? Learn how we're collaborating in this fight against rabies.
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Boehringer and ZEISS partnership eye diseases
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Animal Health Partnering Interests Digital Science May 2024 CORP
Enabling-Today's-Science-Infographic.pdf
Digital_Science.pdf
enabling_todays-science_infographic.pdf
Partnering_In_DIGITAL_SCIENCE_0.pdf
Partnering in Digital Science MAY 2024 CORP_0.pdf
enabling_todays-science_infographic
GioTag-Final-Data Infographic.pdf
EMPRISE Europe Asia data 2021.pdf
Boehringer Ingelheim Academy Video 2023
Boehringer Ingelheim’s Academy initiative provides networking opportunities, education and facilitates conversations across the innovation community.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.